Viewing nowPeloo Odi Tablet 20 mg (Memantine Hydrochloride)
Memantine Hydrochloride 20mg
Orally disintegrating Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.

MFDS item code 202301421 · Approved 2023.05.01 · Insurance code 651905300
Treatment of moderate to severe Alzheimer's disease
This medication is used to treat moderate to severe Alzheimer's disease.
This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. 1. Adults Dose escalation: The maximum daily dose is 20 mg. To minimize the risk of adverse reactions, increase the dose by 5 mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1-7) Administer 5 mg once daily for 7 days. Week 2 (Days 8-14) Administer 10 mg once daily for 7 days. Week 3 (Days 15-21) Administer 15 mg once daily for 7 days. From Week 4 onward Administer 20 mg once daily. Maintenance dose: The recommended maintenance dose is 20 mg once daily. 2. Older adults: Based on clinical data, the recommended dose for patients aged 65 years or older is 20 mg once daily. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10 mg. If well tolerated for at least 7 days after administration, the dose may be increased to 20 mg once daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10 mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medication contains the artificial sweetener aspartame, which is broken down in the body into phenylalanine. Therefore, patients with phenylketonuria, a hereditary condition that requires restriction of phenylalanine intake, should not take this medication. The daily intake of aspartame should be limited to below the WHO recommended amount of 40 mg/kg, and for a 60 kg adult, care should be taken not to exceed a maximum of 2.4 g per day. Persons who are hypersensitive to the components of this medication, or have severe liver or kidney dysfunction should avoid taking it. In particular, it should not be administered to those with severely impaired kidney function (creatinine clearance less than 5 mL/min). Additionally, since this medication contains lactose, patients with genetic problems such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it. Patients with epilepsy or a history of seizures, or those with a predisposition to seizures should use this medication cautiously. Concurrent use with other medications that act on the NMDA receptor may increase central nervous system side effects, so co-administration should be avoided. Care should also be taken in situations that may increase urinary pH, such as changes in diet or certain urinary tract infections, and patients with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension should use this medication carefully. Taking this medication may cause side effects such as dizziness, headache, constipation, drowsiness, and hypertension; central nervous system symptoms such as hallucinations or psychotic reactions have also been reported in some patients. This medication may interact with other drugs; special caution is required when taken with NMDA antagonists, antipsychotics, skeletal muscle relaxants, anticoagulants, and certain gastrointestinal medications due to potential drug concentration changes or increased risk of side effects, and consultation with a doctor or pharmacist is recommended. Pregnant women should use this medication only when deemed necessary due to the risk to the fetus; breastfeeding women are advised to stop breastfeeding as this medication may pass into breast milk. Use in children or adolescents under 18 years is not recommended as the safety and effectiveness of this medication have not been established. In the event of overdose, symptoms such as drowsiness, confusion, hallucinations, seizures, and vomiting may occur; in such cases, prompt medical attention should be sought. This medication may diminish the patient's responsiveness, so caution should be taken when driving or operating machinery. Finally, this medication should be kept out of the reach of children, and transferring it to another container should be avoided as it may pose a risk of accidents and degrade quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is also recommended to keep it in a cool temperature below 30 degrees Celsius.
Flat round orally disintegrating tablets with bright pink speckled pattern and edges.
28 tablets/P-T-P [14 tablets/PTP x 2], 30 tablets/P-T-P [15 tablets/PTP x 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 20mg
Orally disintegrating Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.